non-alcoholic fatty liver disease.
Conditions
Interventions
Intervention 1: Intervention group: Patients with non-alcoholic fatty liver disease receiving 1200 mg hydro alcoholic extract of alfalfa plant per day for 4 weeks. Intervention 2: Control group: Patie
Sponsors
Yasouj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Desire to participate in the study Age 18 to 60 years No history of alcohol consumption Absence of other liver disorders, malignancies, cardiovascular, respiratory and renal disorders No history of weight loss or bariatric surgery in recent years No drug use in the last 3 months and no endocrine and metabolic disorders
Exclusion criteria
Exclusion criteria: Use of drugs or therapies that significantly affect liver function, lipid profile, and markers of oxidative stress and inflammation (eg, rifampin, fibrates, statins, corticosteroids, immunosuppressive agents, antidepressants, cardiac medications such as hydralazine, antibiotics such as tetracycline, sulfonamide, pain relievers such as aspirin, acetaminophen, ibuprofen, anticonvulsants such as phenytoin, valproic acid, carbamazepine, Livorgel, Livorcare, azathiopine). Platelet loss, increase in BUN, cr, disturbance in PTT and other laboratory disturbances during the course of treatment with alpha-alpha plant. The existence of important concomitant diseases such as thyroid diseases, kidney failure, liver disease such as hepatitis, autoimmune, Wilson's disease, cystic fibrosis, hemochromatosis or cardiovascular diseases, rheumatism and lupus, which may interfere with the study results. Having active viral or bacterial infections such as CMV, EBV, TB, etc. Having diseases of the bile and bile ducts History of allergy to alfalfa plant or related plants. Pregnant or lactating women. Alcohol users Inability to provide informed consent or follow study procedures and preference not to continue with the study. The patient's unwillingness to continue participating in the study. Supplement non-adherence (individuals who did not take 90% of the expected capsules at the last visit) Participating in a concurrent trial History of using other herbal medicines during the last three months Any other conditions or conditions that, in the opinion of the researchers, would compromise the safety or validity of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biochemical markers. Timepoint: Zero, 14 and 30 days. Method of measurement: Venous blood sample.;Oxidative stress markers. Timepoint: Zero, 14 and 30 days. Method of measurement: Venous blood sample.;Inflammation markers. Timepoint: Zero, 14 and 30 days. Method of measurement: Venous blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHanieh Pourmehdi Ghaemmaghami
Yasouj University of Medical Sciences
Outcome results
None listed